150 related articles for article (PubMed ID: 27725593)
1. [The importance of taking late cardiovascular toxicity induced by TKI into consideration in patients with CML].
Takahashi N
Rinsho Ketsueki; 2016; 57(10):1956-1961. PubMed ID: 27725593
[TBL] [Abstract][Full Text] [Related]
2. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
3. [Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors].
Matsumura I
Rinsho Ketsueki; 2018; 59(1):13-26. PubMed ID: 29415932
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
6. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
7. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
8. Response-related predictors of survival in CML.
Hanfstein B; Müller MC; Hochhaus A
Ann Hematol; 2015 Apr; 94 Suppl 2():S227-39. PubMed ID: 25814089
[TBL] [Abstract][Full Text] [Related]
9. NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Shah NP
J Natl Compr Canc Netw; 2019 May; 17(5.5):611-613. PubMed ID: 31117031
[TBL] [Abstract][Full Text] [Related]
10. Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach S; Hu Z; Gretzmeier C; Ellermann J; Wöhrle FU; Dengjel J; Brummer T
Cell Commun Signal; 2016 Feb; 14():6. PubMed ID: 26912052
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to therapy in CML.
Bhatia R
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):115-120. PubMed ID: 29222245
[TBL] [Abstract][Full Text] [Related]
12. [Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
Geng SX; Weng JY; Huang X; Lu ZS; Wu P; Huang LS; Liu L; Du X
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):561-5. PubMed ID: 23906446
[TBL] [Abstract][Full Text] [Related]
13. Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
Styles T; Wu M; Wilson R; Babcock F; Butterworth D; West DW; Richardson LC
J Registry Manag; 2016; 41(3):134-142. PubMed ID: 28121314
[TBL] [Abstract][Full Text] [Related]
14. When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently.
Cerveira N; Bizarro S; Teixeira MR; Mariz JM
Curr Treat Options Oncol; 2021 Apr; 22(6):49. PubMed ID: 33866455
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
Carneiro BA; Kaplan JB; Giles FJ
Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
[TBL] [Abstract][Full Text] [Related]
16. Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia.
Pinilla-Ibarz J; Sweet K; Emole J; Fradley M
Anticancer Res; 2015 Dec; 35(12):6355-64. PubMed ID: 26637844
[TBL] [Abstract][Full Text] [Related]
17. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of tyrosine kinase therapy in CML.
Mahon FX
Ann Hematol; 2015 Apr; 94 Suppl 2():S187-93. PubMed ID: 25814085
[TBL] [Abstract][Full Text] [Related]
19. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
20. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
Beel K; Janssens A; Verhoef G; Vandenberghe P
Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]